Kymera Enters a Make-or-Break Clinical Window — Well-Funded, But Binary Outcomes Loom
Kymera (KYMR) combines a late-stage catalyst calendar (Phase 2b for KT-621, Phase 1 start for KT-579) with a strong balance sheet ($1.6B cash, runway into 2029). The stock is trading near $90 and technicals show bullish momentum, but the story is binary: positive clinical readthroughs could re-rate the stock; setbacks could send it sharply lower. W…